TECHNICAL SPECIFICATIONS

Drug / Excipient	
Drug	Sirolimus
Drug Dose	1.12 µg/mm^2
Drug Carrier	Phospholipid

Stent	
Stent Material	L605 Cobalt Chromium Alloy
Strut Thickness	73 µm
Strut Width	80 µm(hinge) - 120 µm (strut)

Delivery System	
Delivery System	RX/Monorail
Nominal Pressure	8 bar
Rated Burst Pressure	14 bar*
Guidewire compatibility (max.)	0.014"
Guiding Catheter Compatibility	5F
Crossing Profile**	0.038"
Tip Entry Profile	0.016"

* Do not exceed RBP
** Reference Diameter of 3.00 mm

ORDERING INFORMATION

Stent Dia (mm)	Stent Length (mm)								
	08	12	16	20	24	28	32	36	40
2.25	EAP22508	EAP22512	EAP22516	EAP22520	EAP22524	EAP22528	EAP22532	EAP22536	EAP22540
2.50	EAP25008	EAP25012	EAP25016	EAP25020	EAP25024	EAP25028	EAP25032	EAP25036	EAP25040
2.75	EAP27508	EAP27512	EAP27516	EAP27520	EAP27524	EAP27528	EAP27532	EAP27536	EAP27540
3.00	EAP30008	EAP30012	EAP30016	EAP30020	EAP30024	EAP30028	EAP30032	EAP30036	EAP30040
3.50	EAP35008	EAP35012	EAP35016	EAP35020	EAP35024	EAP35028	EAP35032	EAP35036	EAP35040
4.00	EAP40008	EAP40012	EAP40016	EAP40020	EAP40024	EAP40028	EAP40032	EAP40036	EAP40040



*The above diagram is just an illustration of the product.
Disclaimer: The law restricts these devices to sale by or on the order of a physician. Indications, contradictions, warnings can be found in the product labelling / IFU supplied with each device. For restricted use only in countries where product is registered with applicable health authorities.

CE 1434

Concept Medical
/conceptmedicals
info@conceptmedical.com
www.conceptmedical.com

Scan for more details

CB.ST.AP.BRO.ver.1.0.21-02

Concept Medical

ABLUMINUS NP

SIROLIMUS BASED NANO CARRIER ELUTING STENT SYSTEM

Digitally signed by Ostapciuc Alexandr
Date: 2024.11.12 11:40:19 EET
Reason: MoldSign Signature
Location: Moldova
MOLDOVA EUROPEANĂ

NON-POLYMER

ABLUMINUS NP

ABLUMINUS NP DEALS WITH HARD FACTS

- HEALING DELAYED
- ACUTE / SUB ACUTE / LATE THROMBOSIS
- RE-STENOSIS FOCAL / EDGE
- DAPT RELATED ISSUES

ABLUMINAL COATING
Drug is coated on the abluminal side only

Leading to unidirectional drug release and less systemic exposure of drug which leads to faster healing

FUSION COATING
(Drug is coated on stent as well as exposed parts of balloon and coated 0.5mm additional beyond the proximal and distal edge of the stent)

Helps to address the entire diseased area of lesion and address the focal restenosis and edge restenosis

POLYMER FREE NANO CARRIER DRUG DELIVERY MATRIX
Designed for acute as well as sustained drug transfer in arterial wall - leading to less chronic inflammation and improved vascular healing

POLYMER FREE COATING
Proposed the shorter DAPT which helps to reduce bleeding risk in patients with high bleeding risk.

MECHANISM OF ACTION



Step 1: Burst drug release from stent and parts of balloon at the time of stent deployment 45 Second inflation holding time recommended



Step 2: Drug release from stent and parts of balloon upon expansion



Step 3: Longer duration Drug release from stent



Step 4: Converts to BMS @ 40 days

NANOACTIVE TECHNOLOGY



Phospholipid drug carrier sub-micron particle

+

Sirolimus sub-micron particle



Sirolimus encapsulated in phospholipid drug carrier

Sirolimus Drug Coating





ADVANTAGE OF NANOACTIVE TECHNOLOGY

- Better in-tissue bioavailability of drug
- Effective drug transfer to the deepest layer of the vessel
- Reduces drug dose
- Protect drug by encapsulation – reduced in-transit drug loss